Which specific critical medicines face potential supply delays?

Question

Accepted Answer

Critical Medicines Under Close Monitoring for Supply Chain Stability

Medicine supplies in Malaysia remain stable and sufficient overall, though a limited number of specific products are subject to ongoing close monitoring due to potential supply chain vulnerabilities. As of May 8, 2026, the Ministry of Health (MOH) identified 118 medicine types, representing 16.8% of tracked products, as high risk due to stock levels below 60 days. Within this high-risk group, 14 specific medicines were flagged as critical. These were identified as critical primarily because they rely on a single registration holder or have experienced delays exceeding one month for incoming shipments.
Identified Critical Medicines and Their Status

The 14 critical medicines identified by the MOH include treatments for serious conditions such as cancer, infections, and diagnostic procedures. Among these are Fluorouracil, a key medication for cancer treatment, and Linezolid, an important antibiotic. Methylene Blue, which is used in diagnostic procedures, and Coal Tar Solution, a treatment for psoriasis, were also listed. These specific items were highlighted due to their supply chain characteristics, which could potentially lead to shortages if not managed proactively.
Stock Levels of Critical Medicines

Despite being classified as critical, detailed checks conducted by the MOH with its facilities and concession companies revealed that 13 out of the 14 identified critical medicines currently maintain stock levels exceeding 90 days. This indicates that immediate shortages are not affecting patient care within MOH facilities. The MOH regularly monitors these stock levels to ensure continuity of treatment for all patients.
Addressing Potential Disruptions and Future Shipments

The remaining item identified among the critical medicines, Carbinoxamine Maleate/Pseudoephedrine Hydrochloride, was noted as not being listed in the MOH Drug Formulary. This means its absence from the formulary does not impact the supply of medicines for patients receiving care at MOH facilities. To further bolster supply chain resilience, additional shipments of critical medicines are scheduled to arrive between June and September. The ministry continues to collaborate with industry stakeholders and healthcare providers to preemptively address any potential supply disruptions.

Reading history

Hide →

This history is cleared when the page is closed.

Which specific critical medicines face potential supply delays?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends